2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $2.7B | $3.8B | $4.8B | $4.7B | $4.7B |
Cost of Revenue | $1.7B | $2.5B | $3.3B | $3.4B | $3.3B |
Gross Profit | $927M | $1.3B | $1.5B | $1.3B | $1.5B |
Gross Profit % | 35% | 34% | 32% | 28% | 31% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $327M | $482M | $419M | $417M | $455M |
Dep. & Amort. | $129M | $145M | $140M | $133M | $127M |
Def. Tax | -$20M | -$47M | -$42M | -$37M | -$64M |
Stock Comp. | $75M | $112M | $100M | $148M | $167M |
Chg. in WC | $24M | -$135M | -$230M | -$125M | -$127M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $1.3B | $1.4B | $1.7B | $2B | $1.3B |
ST Investments | $60M | $0 | $60M | $61M | $1.7M |
Cash & ST Inv. | $1.4B | $1.4B | $1.7B | $2.1B | $1.3B |
Receivables | $501M | $769M | $933M | $897M | $1B |
Inventory | $1 | $0 | $1 | $0 | $0 |
EPAM reported Q4 2024 revenues of $1.25 billion, a 7.9% year-over-year increase, with organic constant currency growth of 1%. Full-year 2024 revenues were $4.73 billion, up 0.8% year-over-year.
The company returned to organic revenue growth in Q4 for the first time since Q1 2023, driven by improved client sentiment and new project starts, particularly in financial services, life sciences, and high-tech verticals.
For 2025, EPAM expects revenue growth of 10%-14%, with approximately 10% coming from inorganic contributions. Q1 2025 revenue guidance is $1.275-$1.29 billion, reflecting 10% year-over-year growth.
Non-GAAP income from operations for 2025 is expected to be in the range of 14.5%-15.5%, with GAAP diluted EPS guidance of $6.78-$7.08 and non-GAAP diluted EPS of $10.45-$10.75.
The company highlighted ongoing investments in Gen AI capabilities, talent retention, and recent acquisitions, which are expected to pressure margins in the near term but position EPAM for long-term growth as demand for advanced AI-native services increases.